Top

General Thoracic and Cardiovascular Surgery

Published in:

01-09-2015 | Original Article

Comparisons of the clinicopathological features and survival outcomes between lung cancer patients with adenocarcinoma and squamous cell carcinoma

Authors: Takayuki Fukui, Tetsuo Taniguchi, Koji Kawaguchi, Koichi Fukumoto, Shota Nakamura, Yukinori Sakao, Kohei Yokoi

Published in: General Thoracic and Cardiovascular Surgery | Issue 9/2015

Abstract

Objective

Patients with lung cancer should be treated according to histological subtype because of the disparities in tumor aggressiveness and treatment responses. It is important to re-evaluate the clinicopathological features of the two major subtypes of lung cancer, adenocarcinoma (AD) and squamous cell carcinoma (SQ).

Methods

We retrospectively analyzed data on the clinicopathological features and outcomes of 2059 patients with pulmonary AD and pulmonary SQ who had undergone complete resection at Nagoya University Hospital and Aichi Cancer Center between 1995 and 2012.

Results

The cohort consisted of 1587 patients with AD (77 %) and 472 with SQ (23 %). Female gender, no history of smoking, and small tumor size were distinct characteristics of AD patients, and a higher age was a characteristic of SQ patients (p < 0.0001). A significant difference was observed in overall survival, with 5-year survival rates of 78 % in AD patients and 63 % in SQ patients. Patients with stage IA and IB SQ had significantly worse outcomes than patients with AD at the same stage (p < 0.0001). Because no survival difference was observed between SQ patients with stage IA, IB, and IIA tumors (p = 0.75), these patients were considered to have proposed stage IIA disease. Then, comparable survival curves were obtained between stages II and IIIA SQ and AD.

Conclusions

Patients with stage I SQ had significantly worse outcomes than patients with stage I AD. A newly defined stage grouping for SQ patients provided outcomes comparable to those of AD patients.

Mountain C. Clinical biology of small cell carcinoma: relationship to surgical therapy. Semin Oncol. 1978;5:272–9.PubMed

Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004;350:2129–39.PubMedCrossRef

Mitsudomi T, Kosaka T, Endoh H, Horio Y, Hida T, Mori S, et al. Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. J Clin Oncol. 2005;23:2513–20.PubMedCrossRef

Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004;304:1497–500.PubMedCrossRef

Hanna N, Shepherd FA, Fossella FV, Pereira JR, De Marinis F, von Pawel J, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol. 2004;22:1589–97.PubMedCrossRef

Scagliotti GV, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol. 2008;26:3543–51.PubMedCrossRef

Reck M, von Pawel J, Zatloukal P, Ramlau R, Gorbounova V, Hirsh V, et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol. 2009;27:1227–34.PubMedCrossRef

Soria JC, Mauguen A, Reck M, Sandler AB, Saijo N, Johnson DH, et al. Systematic review and meta-analysis of randomised, phase II/III trials adding bevacizumab to platinum-based chemotherapy as first-line treatment in patients with advanced non-small-cell lung cancer. Ann Oncol. 2013;24:20–30.PubMedCrossRef

Sawabata N, Miyaoka E, Asamura H, Nakanishi Y, Eguchi K, Mori M, et al. Japanese lung cancer registry study of 11,663 surgical cases in 2004: demographic and prognosis changes over decade. J Thorac Oncol. 2011;6:1229–35.PubMedCrossRef

10.

Maeda R, Yoshida J, Ishii G, Hishida T, Nishimura M, Nagai K. Prognostic impact of histology on early-stage non-small cell lung cancer. Chest. 2011;140:135–45.PubMedCrossRef

11.

Kawase A, Yoshida J, Ishii G, Nakao M, Aokage K, Hishida T, et al. Differences between squamous cell carcinoma and adenocarcinoma of the lung: are adenocarcinoma and squamous cell carcinoma prognostically equal? Jpn J Clin Oncol. 2012;42:189–95.PubMedCrossRef

12.

Aoki T, Tomoda Y, Watanabe H, Nakata H, Kasai T, Hashimoto H, et al. Peripheral lung adenocarcinoma: correlation of thin-section CT findings with histologic prognostic factors and survival. Radiology. 2001;220:803–9.PubMedCrossRef

13.

Fukui T, Sakakura N, Mori S, Hatooka S, Shinoda M, Yatabe Y, et al. Controversy about small peripheral lung adenocarcinomas: how should we manage them? J Thorac Oncol. 2007;2:546–52.PubMedCrossRef

14.

Kodama K, Higashiyama M, Yokouchi H, Takami K, Kuriyama K, Mano M, et al. Prognostic value of ground-glass opacity found in small lung adenocarcinoma on high-resolution CT scanning. Lung Cancer. 2001;33:17–25.PubMedCrossRef

15.

Matsuguma H, Yokoi K, Anraku M, Kondo T, Kamiyama Y, Mori K, et al. Proportion of ground-glass opacity on high-resolution computed tomography in clinical T1 N0 M0 adenocarcinoma of the lung: a predictor of lymph node metastasis. J Thorac Cardiovasc Surg. 2002;124:278–84.PubMedCrossRef

16.

Nakamura S, Fukui T, Taniguchi T, Usami N, Kawaguchi K, Ishiguro F, et al. Prognostic impact of tumor size eliminating the ground glass opacity component: modified clinical T descriptors of the tumor, node, metastasis classification of lung cancer. J Thorac Oncol. 2013;8:1551–7.PubMedCrossRef

17.

Goldstraw P. Staging Manual in Thoracic Oncology. Denver: IASLC; 2009.

18.

Goldstraw P, Crowley J, Chansky K, Giroux DJ, Groome PA, Rami-Porta R, et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours. J Thorac Oncol. 2007;2:706–14.PubMedCrossRef

19.

Rice TW, Blackstone EH, Rusch VW. 7th edition of the AJCC Cancer Staging Manual: esophagus and esophagogastric junction. Ann Surg Oncol. 2010;17:1721–4.PubMedCrossRef

20.

Rice TW, Rusch VW, Ishwaran H, Blackstone EH. Cancer of the esophagus and esophagogastric junction: data-driven staging for the seventh edition of the American Joint Committee on Cancer/International Union Against Cancer Staging Manuals. Cancer. 2010;116:3763–73.PubMedCrossRef

Title: Comparisons of the clinicopathological features and survival outcomes between lung cancer patients with adenocarcinoma and squamous cell carcinoma
Authors: Takayuki Fukui
Tetsuo Taniguchi
Koji Kawaguchi
Koichi Fukumoto
Shota Nakamura
Yukinori Sakao
Kohei Yokoi
Publication date: 01-09-2015
Publisher: Springer Japan
Published in: General Thoracic and Cardiovascular Surgery / Issue 9/2015
Print ISSN: 1863-6705
Electronic ISSN: 1863-6713
DOI: https://doi.org/10.1007/s11748-015-0564-5

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Comparisons of the clinicopathological features and survival outcomes between lung cancer patients with adenocarcinoma and squamous cell carcinoma

Abstract

Objective

Methods

Results

Conclusions

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Objective

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 9/2015

An improved isolation technique for shaggy brachiocephalic artery and aortic arch replacement

A case of focal lung infarction following right upper lobectomy in case of undeveloped lung fissure

Successful repair of aortic annulus rupture during transcatheter aortic valve replacement using extracorporeal membrane oxygenation support

Differing relationship between hypercholesterolemia and a bicuspid aortic valve according to the presence of aortic valve stenosis or aortic valve regurgitation

Right ventricular thrombus in a patient with nephrotic syndrome

Stroke associated with coronary artery bypass grafting